Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors.

Milne K, Köbel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH. · 2009

Read Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. by Milne K, Köbel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2712762.txt.

Introduction

Milne and co-authors analyzed in 2009 which immune cells inside ovarian tumors predict survival, focusing on high-grade serous tumors, the most lethal form. Immune cells in tumors had been linked to better outcomes, but their state and role across tumor types stayed unclear. The team stained tissue arrays for many immune markers at once.

In tumors from patients with the most complete surgery, many T-cell and B-cell markers tracked with longer survival. Three markers stood out as new positive signs: CD20, FoxP3, and TIA-1, with FoxP3 being a surprise since it also marks cells that can damp immunity. Other tumor types had fewer immune cells and far fewer survival links.

Catalog record

CREATORMilne K, Köbel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE64 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2712762

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors By Katy Milne, Martin Köbel, Steven E. Kalloger, Rebecca O. Barnes, Dongxia Gao, C. Blake Gilks, Peter H. Watson, Brad H. Nelson, Derya Unutmaz Published in: PLoS ONE DOI: 10.1371/journal.pone.0006412 ABSTRACT Background Tumor-infiltrating T cells are associated with survival in epithelial ovarian cancer (EOC), but their functional status is poorly understood, especially relative to the different risk categories and histological subtypes of EOC. Methodology/Principal Findings Tissue microarrays containing high-grade serous, endometrioid, mucinous and clear cell tumors were analyzed immunohistochemically for the presence of lymphocytes, dendritic cells, neutrophils, macrophages, MHC class I and II, and various markers of activation and inflammation. In high-grade serous tumors from optimally debulked patients, positive associations were seen between intraepithelial cells expressing CD3, CD4, CD8, CD45RO, CD25, TIA-1, Granzyme B, FoxP3, CD20, and CD68, as well as expression of MHC class I and II by tumor cells. Disease-specific survival was positively associated with the markers CD8, CD3, FoxP3, TIA-1, CD20, MHC class I and class II. In other histological subtypes, immune infiltrates were less prevalent, and the only markers associated with survival were MHC class II (positive association in endometrioid cases) and myeloperoxidase (negative association in clear cell cases). Conclusions/Significance Host immune responses to EOC vary widely according to histological subtype and the extent of residual disease. TIA-1, FoxP3 and CD20 emerge as new positive prognostic factors in high-grade serous EOC from optimally debulked patients. INTRODUCTION Ovarian cancer is the most deadly gynecologic cancer, affecting more than 190,000 women worldwide each year (International Agency for Research on Cancer). Delayed diagnosis and the presence of widely disseminated disease account for the high mortality associated with the disease. Additionally, while a large percentage of patients initially respond well to cytoreductive surgery and standard chemotherapy, the disease usually recurs within 2-5 years as residual tumor cells develop resistance to chemotherapy [1], [2]. Although prognosis is often poor, numerous favorable prognostic indicators have been described, including early stage, low grade and optimal surgical debulking [3], [4]. Several recent studies have analyzed the influence of host immunity on disease prognosis. Tumor-infiltrating CD3+ T cells are strongly associated with favorable prognosis, specifically when CD3+ cells are localized within tumor epithelium [5]-[9]. These findings have been extended to the CD8+ T cell subset in particular [10]-[17], suggesting that cytotoxic T lymphocytes (CTLs) play an important role in the antitumor immune response. Accordingly, other factors associated with CTL responses are also positively associated with survival, including interferon-γ (IFN- γ) [18], [19], the IFN- γ receptor [20], interferon regulatory factor (IRF)-1 [21], IL-18 [22], TNF-α [23], MHC class I [24]-[26], and MHC class I antigen processing machinery [17]. In contrast to CD8+ T cells, several studies have indicated that tumor-infiltrating CD25+FoxP3+ T cells (referred to as regulatory T cells or Tregs) are associated with decreased survival [10], [27]-[29]. Tregs have the ability to suppress proliferation, cytokine production, and cytolytic activity of CD4+ and CD8+ T cells by mechanisms involving cell-to-cell contact and the release of cytokines such as TGF-β [30], [31]. Tregs can also induce an immunosuppressive phenotype in other cell types such as macrophages [32]. Although Tregs have been associated with poor prognosis in many cancers, several exceptions have recently been reported. Leffers et. al. found that FoxP3+ infiltrates in advanced stage EOC were associated with increased survival [14]. Similar findings have been reported in colorectal cancer [33] and lymphoma [34]-[36]. Furthermore, in murine models, FoxP3+ cells can play a positive role in anti-tumor and anti-viral immunity [37], [38]. The precise role of regulatory T cells in cancer outcomes warrants further consideration given that several groups are attempting to enhance tumor immunity by depleting FoxP3+ Tregs from cancer patients [39]-[44], including EOC patients [45]. In addition to Tregs, other cell types reportedly play an immunosuppressive role in EOC. For example, plasmacytoid dendritic cells contribute to immunosuppression by promoting the development or recruitment of interleukin-10-producing CD4+ and CD8+ regulatory T cells [46], [47]. Myeloid dendritic cells (MDCs) impair T cell immunity by expressing B7-H1, a ligand for the inhibitory receptor PD-1 found on T cells [48]. Monocytes and macrophages in the EOC microenvironment can be polarized toward a so-called M2 phenotype, which is typified by the expression of IL-10, TGF-b and scavenger receptors and is thought to promote tumor progression [49], [50], [51]. Under the influence of IL-6 and IL-10, macrophages in EOC can also express B7-H4, which inhibits T cell proliferation [52]. Macrophages also produce CCL22, which promotes Treg recruitment to the tumor environment [32]. Finally, expression of the inflammatory mediator COX-2 in tumor epithelium has been associated with reduced lymphocyte infiltration and poor prognosis in EOC [13], [53]. With the advent of tumor tissue microarray (TMA) technology, a large number of retrospective studies have investigated the relationship between tumor-infiltrating immune cells and prognosis in EOC and other cancers. However, most studies focus on one or a few markers, such that associations between different immunological factors may be missed. Additionally most studies fail to address the different histological subtypes of EOC, which are now recognized to behave as distinct diseases [54]. As a result, there are inconsistencies and unresolved issues in the literature concerning the prognostic significance of different immune cell infiltrates. To address this, we analyzed several large series of EOC tumors, including high-grade serous, endometrioid, clear cell and mucinous subtypes, for the presence of various immune cell infiltrates and inflammatory markers. Our results reveal that high-grade serous tumors have a distinct immunological profile that is strongly associated with patient survival. RESULTS Intraepithelial T cells and associated functional markers in high-grade serous EOC We initially investigated the relationship between immune infiltrates and survival in a cohort of 199 high-grade serous EOC patients. We chose to first focus on high-grade serous cases, as the other histological subtypes exhibit distinct biological and clinical properties that are potentially confounding [54], [55]. This initial cohort was restricted to patients who had undergone optimal cytoreduction (i.e., without evidence of macroscopic residual disease). Patient characteristics are shown in Table 1. [Table: Clinical characteristics of the optimally debulked high-grade serous EOC patient cohort.] The tumors in this initial cohort had been previously assessed by immunohistochemistry (IHC) for a variety of lymphocyte markers, including CD3, CD4, CD8, CD20 and Granzyme B [12]. Intraepithelial lymphocytes (i.e., lymphocytes within the epithelial component of the tumor) were scored as either present (i.e. one or more intraepithelial lymphocytes present in at least one of two 0.6 mm cores) or absent. We re-analyzed this data focusing exclusively on high-grade serous cases. We found that 83.2% (163/196) of evaluable high-grade serous tumors were positive for intraepithelial CD3+ T cells, whereas CD4+ and CD8+ intraepithelial cells were found in 53.4% (103/193) and 84.0% (163/194) of evaluable tumors, respectively (Fig. 1A&B and data not shown). CD4+ and CD8+ cellular infiltrates showed a strong positive association (p<0.0001). Table 2 shows statistical associations for these and all other markers studied in this initial cohort. [Figure: Immunohistochemical analysis of high-grade serous EOC tumors showing infiltrates expressing markers of T cell differentiation and activation.(A) CD4, (B) CD8, (C) CD45RO, (D) OX40, (E) CD25, (F) TIA-1, (G) Granzyme B, and (H) FoxP3. 40X objective.] [Table:

Read the complete text